RESUMEN

INTRODUCTION: Cohort studies from referral centers suggest an increasing burden of functional gastric disorders, with frequent emergency room (ER) visits, hospitalizations, or absenteeism. We hypothesized that recruitment from tertiary care sites skews results and thus investigated the burden of these illnesses, using the population-based data of the Medical Expenditure Panel Survey (MEPS). METHODS: Using MEPS data for the years 2000-2015, demographic, economic, healthcare-related, and quality-of-life indicators were extracted for adults reporting the diagnosis of functional gastric diseases to assess trends and to compare results with data from all adults surveyed. RESULTS: Between 2000 and 2015, 2.7 ± 0.2% of the adults surveyed reported a functional gastric illness. Within the period studied, 28.8 ± 2.8% and 17.9 ± 1.6% of this cohort reported ER visits or hospitalizations, respectively. Only a fraction of these persons attributed the ER visits (22.6 ± 0.9%) or admissions (10.9 ± 0.8%) to the functional gastric disorder. Rates remained stable rates during the period studied. Female sex, measures of physical function, comorbidities, and an income below the poverty line were predictors of healthcare utilization. While utilization was stable over time, annual costs increased by 113.9 ± 16.6% during the study period, outpacing the inflation rate of 37.6%. CONCLUSIONS: Persons with functional gastric disorders have significant healthcare needs and face increasing costs of care, largely due to coexisting illnesses. While it is important to recognize this impact, the need for emergency care or hospitalizations remained stable and lower than reported for patients seen in tertiary referral centers, providing reassuring information for patients and providers.

Asunto(s)

Recursos en Salud/tendencias , Autoinforme , Gastropatías/terapia , Comorbilidad , Servicio de Urgencia en Hospital/tendencias , Femenino , Estado Funcional , Costos de la Atención en Salud/tendencias , Recursos en Salud/economía , Hospitalización/tendencias , Humanos , Masculino , Persona de Mediana Edad , Calidad de Vida , Factores de Riesgo , Determinantes Sociales de la Salud/tendencias , Gastropatías/diagnóstico , Gastropatías/economía , Gastropatías/epidemiología , Factores de Tiempo , Estados Unidos/epidemiología

RESUMEN

Postoperative delayed gastric emptying (DGE) is a very common complication after a pancreaticoduodenectomy (PD). This along with other complications can lead to increased health-care costs. This study investigates the costs and length of stay (LOS) associated with these. A retrospective study of 131 patients undergoing PD between 2000 and 2016 at Loma Linda University Health was performed. Chi-squared test was used to determine statistically significant differences between patients with and without DGE (according to the definition of the International Study Group of Pancreatic Surgery). Multiple logistic and linear regression analyses were performed to obtain adjusted odds ratios for variables of interest in association with DGE and relationship to LOS. Of 150 patients undergoing PD, 131 patients with tumors were analyzed. The overall incidence of DGE was 56 per cent. No pre- or postoperative factors were associated with increased risk of DGE. The median LOS for patients with DGE was 15 days versus 9 days for patients without DGE. Patients with DGE added $21,198 to the overall cost of hospitalization. Fourteen patients (10.7%) were readmitted, of whom 11 were because of DGE. Further studies assessing the utility of intraoperative G-tube placement in decreasing hospital costs and readmissions are needed.

Asunto(s)

Vaciamiento Gástrico , Costos de la Atención en Salud , Pancreaticoduodenectomía/efectos adversos , Gastropatías/etiología , Adolescente , Adulto , Anciano , Anciano de 80 o más Años , Femenino , Costos de la Atención en Salud/estadística & datos numéricos , Humanos , Tiempo de Internación/estadística & datos numéricos , Masculino , Persona de Mediana Edad , Neoplasias Pancreáticas/cirugía , Pancreaticoduodenectomía/economía , Estudios Retrospectivos , Gastropatías/economía , Adulto Joven

RESUMEN

BACKGROUND: For most cancers, only a minority of patients have symptoms meeting the National Institute for Health and Clinical Excellence guidance for urgent referral. For gastro-oesophageal cancers, the 'alarm' symptoms of dysphagia and weight loss are reported by only 32 and 8 % of patients, respectively, and their presence correlates with advanced-stage disease. Electronic clinical decision-support tools that integrate with clinical computer systems have been developed for general practice, although uncertainty remains concerning their effectiveness. The objectives of this trial are to optimise the intervention and establish the acceptability of both the intervention and randomisation, confirm the suitability and selection of outcome measures, finalise the design for the phase III definitive trial, and obtain preliminary estimates of the intervention effect. METHODS/DESIGN: This is a two-arm, multi-centre, cluster-randomised, controlled phase II trial design, which will extend over a 16-month period, across 60 general practices within the North East and North Cumbria and the Eastern Local Clinical Research Network areas. Practices will be randomised to receive either the intervention (the electronic clinical decision-support tool) or to act as a control (usual care). From these practices, we will recruit 3000 adults who meet the trial eligibility criteria and present to their GP with symptoms suggestive of gastro-oesophageal cancer. The main measures are the process data, which include the practitioner outcomes, service outcomes, diagnostic intervals, health economic outcomes, and patient outcomes. One-on-one interviews in a sub-sample of 30 patient-GP dyads will be undertaken to understand the impact of the use or non-use of the electronic clinical decision-support tool in the consultation. A further 10-15 GPs will be interviewed to identify and gain an understanding of the facilitators and constraints influencing implementation of the electronic clinical decision-support tool in practice. DISCUSSION: We aim to generate new knowledge on the process measures regarding the use of electronic clinical decision-support tools in primary care in general and to inform a subsequent definitive phase III trial. Preliminary data on the impact of the support tool on resource utilisation and health care costs will also be collected. TRIAL REGISTRATION: ISRCTN Registry, ISRCTN12595588 .

Asunto(s)

Sistemas de Apoyo a Decisiones Clínicas , Técnicas de Apoyo para la Decisión , Diagnóstico por Computador , Neoplasias Esofágicas/complicaciones , Gastropatías/etiología , Neoplasias Gástricas/complicaciones , Protocolos Clínicos , Análisis Costo-Beneficio , Sistemas de Apoyo a Decisiones Clínicas/economía , Diagnóstico por Computador/economía , Inglaterra , Neoplasias Esofágicas/diagnóstico , Neoplasias Esofágicas/economía , Neoplasias Esofágicas/terapia , Médicos Generales , Costos de la Atención en Salud , Recursos en Salud/economía , Recursos en Salud/estadística & datos numéricos , Humanos , Valor Predictivo de las Pruebas , Pronóstico , Proyectos de Investigación , Medición de Riesgo , Factores de Riesgo , Gastropatías/diagnóstico , Gastropatías/economía , Gastropatías/terapia , Neoplasias Gástricas/diagnóstico , Neoplasias Gástricas/economía , Neoplasias Gástricas/terapia

RESUMEN

INTRODUCTION: Delayed gastric emptying (DGE) is a common complication after pancreaticoduodenectomy (PD), yet it remains incompletely understood. The International Study Group of Pancreatic Surgery (ISGPS) in 2007 defined a three-tiered grading system to standardize studies of DGE. METHODS: In this study, 721 patients undergoing PD between 2006 and 2012 were retrospectively categorized by the ISGPS DGE criteria, as well as a modified grading system (termed primary DGE) if, on retrospective review, DGE was not believed to be a sequela of a separate complication. Predictive factors and associated outcomes were determined. RESULTS: ISGPS-defined DGE occurred in 140 (19.4%) patients. In a multivariate analysis, predictors of ISGPS-defined DGE included abdominal infection (odds ratio (OR) 5.5, p < 0.001), male gender (OR 1.92, p = 0.007), smoking history (OR 1.75 p = 0.033), and periampullary adenocarcinoma (OR 1.66, p = 0.041). Primary DGE occurred in 12.2% of patients. Predictors included abdominal infection (OR 3.15, p < 0.001) and smoking history (OR 2.04, p = 0.008). Median hospital charges increased over $10,000 with each severity grade of DGE (p < 0.001). CONCLUSION: DGE is common after PD and contributes substantially to cost. DGE is frequently a secondary complication of abdominal infection, and interventions that limit such complications may be the most effective strategy toward preventing DGE.

Asunto(s)

Adenocarcinoma/cirugía , Neoplasias del Sistema Digestivo/cirugía , Vaciamiento Gástrico , Pancreaticoduodenectomía/efectos adversos , Gastropatías/diagnóstico , Gastropatías/fisiopatología , Adulto , Anciano , Anciano de 80 o más Años , Femenino , Humanos , Infecciones Intraabdominales/complicaciones , Masculino , Persona de Mediana Edad , Análisis Multivariante , Recuperación de la Función , Estudios Retrospectivos , Factores de Riesgo , Factores Sexuales , Fumar , Gastropatías/economía , Factores de Tiempo , Adulto Joven

RESUMEN

INTRODUCTION: Gastrointestinal hemorrhage due to vascular malformations has a negative impact on patients´ quality of life and consumes an important quantity of resources. OBJECTIVE: Analyze the cost-effectiveness of long-active releasing octreotide (OCT-LAR) in the treatment of gastrointestinal haemorrhage secondary to vascular malformations. MATERIAL AND METHODS: Retrospective study, including 19 pacients that were treated with mensual injections of OCTLAR between 2008-2013. The number of blood transfusions, hemoglobin levels, hospital admissions and possible side effects during the year before treatment and the year after the start of the treatment were assessed, and cost-effectiveness was analyzed. RESULTS: After the beginning of the treatment with OCTLAR, complete response was observed in 7 patients (36.8 %), partial response in 7 patients (36.8 %) and 5 patients (26.3 %) continued to require admissions, blood transfusions and/or endoscopic treatment. We observed significant reduction in the length of admission per year (in days) before and after the start of the treatment (22.79 versus 2.01 days, p < 0.0001) as well as in the number of blood transfusions administered (11.19 versus 2.55 blood transfusions per year, p = 0.002). The mean haemoglobin levels increased from 6.9 g/dl to 10.62 g/dl (p < 0.0001). We observed reduction of costs of 61.5 % between the two periods (from 36,072.35 € to 13,867.57 € per patient and year, p = 0.01). No side effects related to treatment were described. CONCLUSION: In conclusion, OCT-LAR seems to be a costefficient and safe pharmacological treatment of gastrointestinal haemorrhage secondary to vascular malformations, mainly in patients in whom endoscopic or surgical treatment is contraindicated.

Asunto(s)

Angiodisplasia/complicaciones , Análisis Costo-Beneficio , Fármacos Gastrointestinales/administración & dosificación , Hemorragia Gastrointestinal/tratamiento farmacológico , Octreótido/administración & dosificación , Gastropatías/tratamiento farmacológico , Anciano , Anciano de 80 o más Años , Angiodisplasia/economía , Preparaciones de Acción Retardada , Esquema de Medicación , Femenino , Ectasia Vascular Antral Gástrica/complicaciones , Ectasia Vascular Antral Gástrica/economía , Fármacos Gastrointestinales/economía , Fármacos Gastrointestinales/uso terapéutico , Hemorragia Gastrointestinal/economía , Hemorragia Gastrointestinal/etiología , Humanos , Inyecciones Intramusculares , Masculino , Persona de Mediana Edad , Octreótido/economía , Octreótido/uso terapéutico , Estudios Retrospectivos , España , Gastropatías/economía , Gastropatías/etiología

RESUMEN

BACKGROUND/AIMS: To determine risk factors associated with mortality and increased drug costs in patients with nonvariceal upper gastrointestinal bleeding. METHODOLOGY: We retrospectively analyzed data from patients hospitalized with nonvariceal upper gastrointestinal bleeding between January 2001-December 2011. Demographic and clinical characteristics and drug costs were documented. Univariate analysis determined possible risk factors for mortality. Statistically significant variables were analyzed using a logistic regression model. Multiple linear regression analyzed factors influencing drug costs. p < 0.05 was considered statistically significant. RESULTS: The study included data from 627 patients. Risk factors associated with increased mortality were age > 60, systolic blood pressure<100 mmHg, lack of endoscopic examination, comorbidities, blood transfusion, and rebleeding. Drug costs were higher in patients with rebleeding, blood transfusion, and prolonged hospital stay. CONCLUSION: In this patient cohort, re-bleeding rate is 11.20% and mortality is 5.74%. The mortality risk in patients with comorbidities was higher than in patients without comorbidities, and was higher in patients requiring blood transfusion than in patients not requiring transfusion. Rebleeding was associ-ated with mortality. Rebleeding, blood transfusion, and prolonged hospital stay were associated with increased drug costs, whereas bleeding from lesions in the esophagus and duodenum was associated with lower drug costs.

Asunto(s)

Costos de los Medicamentos/estadística & datos numéricos , Úlcera Duodenal/mortalidad , Hemorragia Gastrointestinal/mortalidad , Úlcera Péptica Hemorrágica/mortalidad , Úlcera Gástrica/mortalidad , Adulto , Factores de Edad , Anciano , Antiinflamatorios no Esteroideos/efectos adversos , Coagulación con Plasma de Argón , Presión Sanguínea , Transfusión Sanguínea/estadística & datos numéricos , Estudios de Cohortes , Comorbilidad , Estudios Transversales , Enfermedades Duodenales/economía , Enfermedades Duodenales/mortalidad , Enfermedades Duodenales/terapia , Úlcera Duodenal/economía , Úlcera Duodenal/terapia , Endoscopía del Sistema Digestivo/estadística & datos numéricos , Epinefrina/uso terapéutico , Enfermedades del Esófago/economía , Enfermedades del Esófago/mortalidad , Enfermedades del Esófago/terapia , Femenino , Hemorragia Gastrointestinal/economía , Hemorragia Gastrointestinal/terapia , Hemostáticos/uso terapéutico , Humanos , Tiempo de Internación , Modelos Lineales , Masculino , Síndrome de Mallory-Weiss/economía , Síndrome de Mallory-Weiss/mortalidad , Síndrome de Mallory-Weiss/terapia , Persona de Mediana Edad , Análisis Multivariante , Úlcera Péptica Hemorrágica/economía , Úlcera Péptica Hemorrágica/terapia , Recurrencia , Estudios Retrospectivos , Factores de Riesgo , Gastropatías/inducido químicamente , Gastropatías/economía , Gastropatías/mortalidad , Gastropatías/terapia , Úlcera Gástrica/economía , Úlcera Gástrica/terapia , Trombina/uso terapéutico , Vasoconstrictores/uso terapéutico

RESUMEN

BACKGROUND: Progression of extensive gastric premalignant conditions to cancer might warrant surveillance programms. Recent guidelines suggest a 3-yearly endoscopic follow-up for these patients. Our aim was to determine the cost utility of endoscopic surveillance of patients with extensive gastric premalignant conditions such as extensive atrophy or intestinal metaplasia. MATERIALS AND METHODS: A cost-utility economic analysis was performed from a societal perspective in Portugal using a Markov model to compare two strategies: surveillance versus no surveillance. Clinical data were collected from a systematic review of the literature, costs from published national data, and community utilities derived from a population study by the EuroQol questionnaire in terms of quality-adjusted life years (QALY). Population started at age 50, for a time horizon of 25 years and an annual discount rate of 3% was used for cost and effectiveness. Primary outcome was the incremental cost-effectiveness ratio (ICER) of a 3-yearly endoscopic surveillance versus no surveillance for a base case scenario and in deterministic and probabilistic sensitivity analysis. Secondary outcomes were ICER of 5- and 10-yearly endoscopic surveillance versus no surveillance. RESULTS: Endoscopic surveillance every 3 years provided an ICER of € 18,336, below the adopted threshold of € 36,575 which corresponds to the proposed guideline limit of USD 50,000 and this strategy dominated surveillance every 5 or 10 years. Utilities for endoscopic treatment were relevant in deterministic analysis, while probabilistic analysis showed that in 78% of cases the model was cost-effective. CONCLUSIONS: Endoscopic surveillance every 3 years of patients with premalignant conditions is cost-effective.

Asunto(s)

Análisis Costo-Beneficio/economía , Endoscopía/economía , Lesiones Precancerosas/economía , Gastropatías/economía , Adulto , Anciano , Análisis Costo-Beneficio/métodos , Femenino , Humanos , Lesiones Precancerosas/diagnóstico , Lesiones Precancerosas/patología , Vigilancia de Guardia , Gastropatías/diagnóstico , Gastropatías/patología

RESUMEN

We aimed to determine the economic impact of absenteeism and presenteeism from five conditions potentially comorbid with depressive symptoms-back or neck disorders, depression, anxiety, or emotional disorders, chronic headaches, stomach or bowel disorders, and insomnia-among Japanese workers aged 18-59 yr. Participants from 19 workplaces anonymously completed Stanford Presenteeism Scale questionnaires. Participants identified one primary health condition and determined the resultant performance loss (0-100%) over the previous 4-wk period. We estimated the wage loss by gender, using 10-yr age bands. A total of 6,777 participants undertook the study. Of these, we extracted the data for those in the 18-59 yr age band who chose targeted primary health conditions (males, 2,535; females 2,465). The primary health condition identified was back or neck disorders. We found that wage loss due to presenteeism and absenteeism per 100 workers across all 10-yr age bands was high for back or neck disorders. Wage loss per person was relatively high among those identifying depression, anxiety, or emotional disorders. These findings offer insight into developing strategies for workplace interventions on increasing work performance.

Asunto(s)

Absentismo , Eficiencia Organizacional/economía , Trastornos Mentales/economía , Trastornos Mentales/epidemiología , Salarios y Beneficios/estadística & datos numéricos , Adolescente , Adulto , Factores de Edad , Dolor de Espalda/economía , Dolor de Espalda/epidemiología , Comorbilidad , Femenino , Trastornos de Cefalalgia/economía , Trastornos de Cefalalgia/epidemiología , Humanos , Enfermedades Intestinales/economía , Enfermedades Intestinales/epidemiología , Japón/epidemiología , Masculino , Persona de Mediana Edad , Dolor de Cuello/economía , Dolor de Cuello/epidemiología , Factores Sexuales , Trastornos del Inicio y del Mantenimiento del Sueño/economía , Trastornos del Inicio y del Mantenimiento del Sueño/epidemiología , Gastropatías/economía , Gastropatías/epidemiología , Encuestas y Cuestionarios , Adulto Joven

Asunto(s)

Abomaso/patología , Enfermedades de los Bovinos/terapia , Gastropatías/veterinaria , Medicina Veterinaria/normas , Animales , Bovinos , Enfermedades de los Bovinos/economía , Industria Lechera , Técnicas de Apoyo para la Decisión , Atención a la Salud , Gastropatías/economía , Gastropatías/patología , Gastropatías/terapia , Medicina Veterinaria/economía

RESUMEN

OBJECTIVE: To use decision and sensitivity analysis to examine the delivery of health care on US dairy farms as measured by correction of left displaced abomasum (LDA). SAMPLE POPULATION: 5 journal articles evaluating outcomes from veterinarian- or herd personnel-delivered correction of LDA via laparotomy or a roll-and-toggle procedure. DESIGN: Economic analysis. PROCEDURES: A decision tree was constructed on the basis of published outcome data for correction of LDAs performed by veterinarians and herd personnel. Sensitivity of the model to changing input assumptions was evaluated via an indifference curve and tornado graph. RESULTS: Decision tree analysis revealed that correction of an LDA provided by herd personnel had an expected economic advantage of $76, compared with correction provided by a veterinarian. Sensitivity of this analysis to variations in inputs indicated that changes of 2 input levels would shift the advantage to veterinarian-provided correction: a reduction (from 0.74 to 0.62) in the probability of success for correction provided by herd personnel or an increase (from 0.78 to 0.87) in the probability of success for correction provided by a veterinarian. CONCLUSIONS AND CLINICAL RELEVANCE: In this model, LDA correction by herd personnel had a significant economic advantage, compared with veterinarian-provided correction. Continued absorption of traditional veterinary tasks by unlicensed herd personnel may threaten the veterinarian-client-patient relationship (VCPR), which could have profound economic and regulatory impacts. Food animal veterinarians need to evaluate their business model to ensure they continue to provide relevant, sustainable services to their clients within the context of a valid VCPR.

Asunto(s)

Abomaso/patología , Enfermedades de los Bovinos/terapia , Industria Lechera , Gastropatías/veterinaria , Medicina Veterinaria/normas , Animales , Bovinos , Enfermedades de los Bovinos/economía , Técnicas de Apoyo para la Decisión , Atención a la Salud , Gastropatías/economía , Gastropatías/patología , Gastropatías/terapia , Medicina Veterinaria/economía

RESUMEN

Nonsteroidal anti-inflammatory drugs (NSAIDs) are extensively used worldwide. However, associated adverse gastrointestinal effects (NSAID gastropathy) such as bleeding, perforation and obstruction result in considerable morbidity, mortality, and expense. Although it is essential to employ gastroprotective strategies to minimize these complications in patients at risk, controversy remains on whether celecoxib alone or a non-selective NSAID in conjunction with a proton-pump inhibitor (PPI) is a superior choice. Recent concerns regarding potential cardiovascular toxicities associated with cox-2 selective inhibitors may favor non-selective NSAID/PPI co-therapy as the preferred choice. Concomitant use of low-dose aspirin with any NSAID increases the risk of gastrointestinal complications and diminishes the improved gastrointestinal safety profile of celecoxib; whereas use of ibuprofen plus PPI regimens may negate aspirin's antiplatelet benefits. Evidence shows that concurrent use of a non-selective NSAID (such as naproxen) plus a PPI is as effective in preventing NSAID gastropathy as celecoxib, and may be more cost-effective. Patients failing or intolerant to this therapy would be candidates for celecoxib at the lowest effective dose for the shortest duration of time. Potential benefits from using low-dose celecoxib with a PPI in patients previously experiencing bleeding ulcers while taking NSAIDs remains to be proven. An evidence-based debate is presented to assist clinicians with the difficult decision-making process of preventing NSAID gastropathy while minimizing other complications.

Asunto(s)

Antiinflamatorios no Esteroideos/efectos adversos , Aspirina/efectos adversos , Inhibidores de la Ciclooxigenasa/efectos adversos , Infarto del Miocardio/inducido químicamente , Inhibidores de la Bomba de Protones , Pirazoles/uso terapéutico , Gastropatías/inducido químicamente , Sulfonamidas/uso terapéutico , Anciano , Antiinflamatorios no Esteroideos/uso terapéutico , Celecoxib , Inhibidores de la Ciclooxigenasa/uso terapéutico , Toma de Decisiones , Sinergismo Farmacológico , Medicina Basada en la Evidencia , Humanos , Persona de Mediana Edad , Infarto del Miocardio/mortalidad , Pirazoles/efectos adversos , Pirazoles/economía , Ensayos Clínicos Controlados Aleatorios como Asunto , Gastropatías/economía , Gastropatías/prevención & control , Sulfonamidas/efectos adversos , Sulfonamidas/economía

RESUMEN

BACKGROUND AND OBJECTIVE: 13C-urea breath tests have become clinical routine in the diagnosis of Helicobacter pylori infection. For the analysis of the 13CO2/12CO2 enrichment in breath, less expensive alternatives to the expensive mass spectrometry (IRMS) have been developed, based on isotope-selective infrared spectroscopy (NDIRS). In this prospective study we tested under clinical conditions a simplified and thus less expensive NDIR-spectrometer by comparing it with mass spectroscopy. METHODS: 100 patients (53 men, 47 women, mean age 59+/-14 years) with dyspeptic symptoms were tested for Helicobacter pylori infection using the 13C-urea breath test. The isotope ratio analysis of the breath samples was performed in duplicate, both using IRMS and NDIRS. RESULTS: The results of the baseline-corrected 13CO2 -exhalation values between IRMS and NDIRS were in excellent agreement. The mean difference between both methods was 0.05+/-1.16 . Evaluating the qualitative urea breath test results in reference to IRMS as the reference, the NDIRS had a sensitivity of 95 % and a specificity of 99 %. CONCLUSION: This newly developed isotope-selective nondispersive infrared spectroscopy is going to become a reliable, and low-cost alternative to expensive isotope ratio mass spectrometry in the analysis of 13C-breath tests. All these characteristics make NDIRS particularly suitable for laboratories where the daily number of assays is small or for use in the doctor's office

Asunto(s)

Pruebas Respiratorias/instrumentación , Infecciones por Helicobacter/diagnóstico , Helicobacter pylori , Espectroscopía Infrarroja Corta/instrumentación , Gastropatías/diagnóstico , Urea , Adulto , Anciano , Dióxido de Carbono/análisis , Isótopos de Carbono , Análisis Costo-Beneficio , Dispepsia/etiología , Diseño de Equipo , Femenino , Infecciones por Helicobacter/economía , Humanos , Masculino , Espectrometría de Masas/economía , Espectrometría de Masas/instrumentación , Persona de Mediana Edad , Valor Predictivo de las Pruebas , Espectroscopía Infrarroja Corta/economía , Gastropatías/economía

RESUMEN

Nonsteroidal anti-inflammatory drugs (NSAIDs) are popular and important for the treatment of inflammation and pain. However, conventional NSAIDs are intrinsically toxic to the gastroduodenal (GD) mucosa. The literature can, and should, guide us towards safer prescribing of NSAIDs. Factors known to increase the risk of GD toxicity include: history of peptic ulcer disease; advanced age; high doses; and coadministration of aspirin, anticoagulants or corticosteroids. Patients with any one of these risk factors, with the possible exception of age alone, should receive gastroprotective prophylaxis with proton pump inhibitors or misoprostol. Standard dose H2 antagonists do not protect against NSAID-induced gastric ulcers and are unsuitable for prophylaxis. Awareness of risk factors and appropriate prophylactic agents will minimize the risk to patients. Whether the new generation of highly selective COX-2 inhibitors and nitric oxide-donating NSAIDs are safer drugs in long-term use be remains to be proven, though initial clinical trial data are positive.

Asunto(s)

Antiinflamatorios no Esteroideos/efectos adversos , Enfermedades Duodenales/inducido químicamente , Gastropatías/inducido químicamente , Antiinflamatorios no Esteroideos/economía , Antiulcerosos/economía , Antiulcerosos/uso terapéutico , Enfermedades Duodenales/economía , Enfermedades Duodenales/prevención & control , Humanos , Gastropatías/economía , Gastropatías/prevención & control

Asunto(s)

Antiinflamatorios no Esteroideos/efectos adversos , Butanonas/clasificación , Inhibidores de la Ciclooxigenasa/efectos adversos , Gastropatías/inducido químicamente , Gastropatías/prevención & control , Celecoxib , Ensayos Clínicos como Asunto , Factores de Confusión Epidemiológicos , Quimioterapia Combinada , Humanos , Lactonas/efectos adversos , Meloxicam , Nabumetona , Pirazoles , Gastropatías/economía , Sulfonamidas/efectos adversos , Sulfonas , Tiazinas/efectos adversos , Tiazoles/efectos adversos

Asunto(s)

Antiinflamatorios no Esteroideos/efectos adversos , Antiulcerosos/economía , Antiulcerosos/uso terapéutico , Inhibidores Enzimáticos/economía , Inhibidores Enzimáticos/uso terapéutico , Infecciones por Helicobacter/tratamiento farmacológico , Infecciones por Helicobacter/economía , Gastropatías/tratamiento farmacológico , Gastropatías/economía , Antiinflamatorios no Esteroideos/uso terapéutico , Análisis Costo-Beneficio , Quimioterapia Combinada , Infecciones por Helicobacter/complicaciones , Infecciones por Helicobacter/microbiología , Helicobacter pylori , Humanos , Misoprostol/economía , Misoprostol/uso terapéutico , Omeprazol/economía , Omeprazol/uso terapéutico , Gastropatías/inducido químicamente

RESUMEN

Nonsteroidal anti-inflammatory drugs (NSAIDs) are commonly used to manage arthritis. While controlling symptoms and improving quality of life, NSAID use is associated with gastroduodenal injury and a 2%-4% annual risk for symptomatic gastroduodenal ulceration, hemorrhage, and perforation. This requires clinicians to balance the efficacy of NSAIDs against the potential risk of serious gastrointestinal events. Identification and stratification of risk can help guide the optimal approach for arthritis management of individual patients or large populations such as managed care organizations. NSAID-induced gastroenteropathy carries considerable economic consequences; 46% of arthritis costs are related to managing serious adverse events. It is reasonable to assume that these costs may not be incurred if high-risk patients are recognized and optimally managed. Newer therapies with proven safety margins present an attractive option, especially for patients at higher risk. The single-tablet formulations of diclofenac and misoprostol (Arthrotec) offer an alternative in managing NSAID patients because of their inherent safety profile. Studies with diclofenac/misoprostol indicate its effectiveness in treating signs and symptoms of arthritis and in reducing the incidence of NSAID-induced gastroenteropathy. As such, this agent may provide improved medical and economic outcomes. This review discusses the clinical aspects of NSAID-induced gastroenteropathy, including available preventive therapies. Approaches to assessing patients' risk for developing complications, and the relationship of medical risk and economic outcomes, are also examined. Although not all patients require preventive therapy, patients with heightened risk may benefit clinically and economically from gastroprotective NSAIDs. Additional research or modeling may provide further insight into the economic implications of managing and preventing NSAID-induced gastroenteropathy.

Asunto(s)

Antiinflamatorios no Esteroideos/efectos adversos , Artritis/tratamiento farmacológico , Costo de Enfermedad , Diclofenaco/efectos adversos , Misoprostol/efectos adversos , Gastropatías/inducido químicamente , Gastropatías/economía , Antiinflamatorios no Esteroideos/administración & dosificación , Antiinflamatorios no Esteroideos/economía , Canadá , Diclofenaco/administración & dosificación , Diclofenaco/economía , Combinación de Medicamentos , Humanos , Misoprostol/administración & dosificación , Misoprostol/economía , Modelos Econométricos , Factores de Riesgo , Gastropatías/fisiopatología , Gastropatías/prevención & control , Estados Unidos

RESUMEN

The use of nonsteroidal anti-inflammatory drugs (NSAIDs) is associated with a 2% to 4% annual incidence of serious gastrointestinal complications. These adverse clinical outcomes, and the strategies used to prevent their occurrence, translate into a significant economic burden. A decision-analysis model was constructed to contrast the 6-month costs associated with various approaches to preventing and managing NSAID-induced gastropathy and to evaluate the economic impact of two treatment regimens using fixed-dose formulations of diclofenac/misoprostol. After incorporating expected medical out-comes and predicted practice patterns, 6-month per-patient costs were derived from the model for each of five treatment regimens: (1) NSAID alone; (2) NSAID with a histamine2-receptor antagonist; (3) NSAID with coprescribed misoprostol; (4) diclofenac/misoprostol 50 mg/200 micrograms TID/BID; and (5) diclofenac/misoprostol 75 mg/200 micrograms BID. The combined diclofenac/misoprostol regimens demonstrated an 18.6% per-patient cost advantage compared with the combined NSAID regimens. Based on a 6-month period, this cost savings translated into a $214.00 per-patient overall cost savings ($1153.00 per patient for NSAID regimens versus $939.00 for diclofenac/misoprostol regimens). The magnitude of this difference was verified by Monte Carlo simulation. Despite the considerable cost difference, sensitivity analyses revealed that our model was robust and that no single variation substantially influenced the results. Given the lack of long-term prospective, comparative clinical-outcomes studies in this area, this decision analysis provides guidance to clinicians in developing a rational and cost-effective approach to the treatment of patients requiring chronic NSAID therapy.

Asunto(s)

Antiinflamatorios no Esteroideos/efectos adversos , Antiinflamatorios no Esteroideos/economía , Gastropatías/inducido químicamente , Gastropatías/economía , Costos y Análisis de Costo , Técnicas de Apoyo para la Decisión , Humanos , Modelos Económicos , Método de Montecarlo , Gastropatías/prevención & control

RESUMEN

Seventy-two lactating dairy cows with left displacement of the abomasum were blindly assigned to treatment by use of the roll-and-toggle procedure or right paralumbar fossa pyloro-omentopexy. All cows were from the same large dairy herd, and survival in the herd and daily milk production were measured for 120 days after treatment. The mean cost was $256.50 for roll-and-toggle cases ($50 for the procedure, $95.70 in milk loss and $110.80 in livestock losses). The mean cost was $406.40 for the pyloro-omentopexy cases ($150 for the procedure, $87.80 in milk loss, and $168.60 in livestock losses). A possible interaction with metritis was discovered, in that pyloro-omentopexy cases cost about $100 more than roll-and-toggle cases when metritis was absent (31 cases) or moderate (32 cases), and cost several times more when metritis was severe (9 cases). Results of the study were in agreement with those of other studies that indicated that the closed repositioning and stabilization techniques are generally less expensive and have comparable results with open repositioning and stabilization techniques. Veterinarians may wish to consider use of this nonsurgical technique for the routine correction of left displacement of the abomasum in dairy cattle.

Asunto(s)

Abomaso , Enfermedades de los Bovinos/terapia , Epiplón/cirugía , Antro Pilórico/cirugía , Gastropatías/veterinaria , Animales , Bovinos , Enfermedades de los Bovinos/economía , Enfermedades de los Bovinos/cirugía , Costos y Análisis de Costo , Industria Lechera/economía , Endometritis/economía , Endometritis/veterinaria , Femenino , Lactancia , Gastropatías/economía , Gastropatías/cirugía , Gastropatías/terapia , Técnicas de Sutura/economía , Técnicas de Sutura/veterinaria

RESUMEN

In order to obtain information on prescribing habits concerning the prevention of gastroduodenal lesions induced by non-steroidal anti-inflammatory agents (NSAI), 356 physicians practicing in 2 French departments were asked to fill a posted questionnaire. Fifty-one percent of these doctors gave an assessable answer. Among these, 84 percent occasionally prescribe "gastric protectors" associated with NSAI's in 32 percent of the prescriptions. They use antacids (48 percent), anti-H2 products (27 percent), sucralfate (11 percent) or prostaglandins (13 percent). This represents a daily cost of additional treatment ranging from 0.87 to 2.49 francs. If fibroscopies and further consultations necessitated by the prescription of NSAI's are taken into account, then 86 to 140 percent must be added to the cost of NSAI's. The profitability of these preventive measures in terms of public health will be really estimated only when the number of severe gastroduodenal lesions effectively prevented by taking topical gastric protectors or anti-secretory agents will be known.

Asunto(s)

Antiácidos/uso terapéutico , Antiinflamatorios no Esteroideos/efectos adversos , Enfermedades Duodenales/prevención & control , Antagonistas de los Receptores H2 de la Histamina/uso terapéutico , Gastropatías/prevención & control , Enfermedades Duodenales/inducido químicamente , Enfermedades Duodenales/economía , Femenino , Francia , Encuestas Epidemiológicas , Humanos , Masculino , Factores de Riesgo , Gastropatías/inducido químicamente , Gastropatías/economía , Encuestas y Cuestionarios

RESUMEN

Nonsteroidal anti-inflammatory drug (NSAID) use and gastrointestinal (GI) injury and symptoms are associated in clinical practice, but the importance of this injury is debatable. Most rheumatologists and general practitioners view NSAIDs as extremely valuable and generally well-tolerated first-line agents in the treatment of arthritis and musculoskeletal disorders. Generally, gastroenterologists and surgeons, on the other hand, insist that NSAIDs are dangerous and potentially lethal irritants to the GI mucosa. More frequent NSAID-induced gastropathy may be related to general epidemiological trends in NSAID-using populations: longer life expectancy, multiple risk co-factors for peptic ulcer disease (ie, smoking, alcohol, diet, comedication), and the increased availability of endoscopic examinations. Based on endoscopic studies, the prevalence of NSAID-induced adverse GI events has been documented in published reports. The frequency of bleeding is related to dose and duration of NSAID therapy. Overall, the prevalence of ulcer complications is higher in patients who consume NSAIDs. Cost-benefit analyses indicate that preventing potential GI damage with agents such as misoprostol may reduce the expense of treating the GI side effects associated with NSAID therapy.

Asunto(s)

Antiinflamatorios no Esteroideos/efectos adversos , Gastropatías/inducido químicamente , Costos de los Medicamentos , Endoscopía , Costos de la Atención en Salud , Humanos , Mortalidad , Gastropatías/economía , Gastropatías/epidemiología